The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | ZUMA-5: high ORR and CR for R/R iNHL with axi-cel
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, gives an update on the ongoing Phase II ZUMA-5 trial (NCT03105336) of axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR)-T cell therapy, for patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma and marginal zone lymphoma (MZL). Axi-cel has demonstrated a high overall response rate (ORR) at 92% and a high complete response (CR) rate at 76% in patients with iNHL at a median follow-up of 17.5 months. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
